Literature DB >> 17550984

Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.

Jill M Siegfried1, Christopher T Gubish, Mary E Rothstein, Pierre E Queiroz de Oliveira, Laura P Stabile.   

Abstract

Many studies have suggested a role for the hepatocyte growth factor (HGF)/c-Met pathway in tumorigenesis. Some actions of HGF are believed to be mediated by cyclooxygenase-2 (COX-2), resulting in the production of prostaglandin E2 (PGE(2)). We examined four c-Met-positive non-small-cell lung cancer (NSCLC) cell lines for effects of HGF on COX-2. HGF increased COX-2 protein expression 3-fold over basal levels. Induction of COX-2 occurred through both the extracellular signal-regulated kinase 1/2 and p38 pathways. HGF treatment caused activation of the activator protein-1, CCAAT/enhancer-binding protein, and cAMP response element-binding protein transcription factors, and COX-2 induction was blocked by actinomycin D. The half-life of COX-2 mRNA was also increased by HGF. HGF stimulation resulted in a 4-fold increase in PGE(2) secretion, and treatment of NSCLC cells with exogenous PGE(2) significantly increased cell proliferation. The addition of PGE(2) to NSCLC cells also led to rapid phosphorylation of c-Met in the absence of HGF, which was blocked by epidermal growth factor receptor (EGFR) inhibition. EGFR ligands were released in response to PGE(2). This suggests that secretion of PGE(2) induced by HGF/c-Met pathway activation can further activate the c-Met pathway via EGFR in a reinforcing loop that is independent of HGF. HGF and PGE(2) each significantly stimulated invasion in NSCLC cells. Cells transiently transfected with c-Met antisense plasmid showed a significant decrease in HGF- or PGE(2)-induced invasion. PGE(2)-induced invasion was EGFR-dependent, confirming a link between PGE(2), EGFR, and c-Met. Targeting of both the HGF/c-Met and PGE(2) pathways with a neutralizing antibody to HGF and celecoxib resulted in enhanced anti-invasion effects in response to HGF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17550984     DOI: 10.1124/mol.107.034215

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.

Authors:  Daisuke Matsubara; Shumpei Ishikawa; Oguni Sachiko; Hiroyuki Aburatani; Masashi Fukayama; Toshiro Niki
Journal:  Am J Pathol       Date:  2010-10-07       Impact factor: 4.307

2.  Hepatocyte growth factor promotes proliferation, invasion, and metastasis of myeloid leukemia cells through PI3K-AKT and MAPK/ERK signaling pathway.

Authors:  Jiang-Rui Guo; Wei Li; Yong Wu; Lin-Qing Wu; Xin Li; Ya-Fei Guo; Xiao-Hui Zheng; Xiao-Lan Lian; Hui-Fang Huang; Yuan-Zhong Chen
Journal:  Am J Transl Res       Date:  2016-09-15       Impact factor: 4.060

3.  Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2.

Authors:  Wenbin Kuang; Qiuchan Deng; Chuntao Deng; Wensheng Li; Shaowei Shu; Meirong Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.

Authors:  Weiping Zhang; Neil Bhola; Shailaja Kalyankrishna; William Gooding; Jennifer Hunt; Raja Seethala; Jennifer R Grandis; Jill M Siegfried
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

5.  Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.

Authors:  Laura P Stabile; Mary E Rothstein; Christopher T Gubish; Diana E Cunningham; Nathan Lee; Jill M Siegfried
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609

6.  Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition.

Authors:  Gaurav Kumar; S Nahum Goldberg; Yuanguo Wang; Erik Velez; Svetlana Gourevitch; Eithan Galun; Muneeb Ahmed
Journal:  Eur Radiol       Date:  2016-06-10       Impact factor: 5.315

7.  Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.

Authors:  Laura P Stabile; Mary E Rothstein; Phouthone Keohavong; Jide Jin; Jinling Yin; Stephanie R Land; Sanja Dacic; The Minh Luong; K Jin Kim; Austin M Dulak; Jill M Siegfried
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

8.  Hepatocyte growth factor regulates cyclooxygenase-2 expression via beta-catenin, Akt, and p42/p44 MAPK in human bronchial epithelial cells.

Authors:  Young H Lee; Yuichiro J Suzuki; Autumn J Griffin; Regina M Day
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-02-01       Impact factor: 5.464

9.  Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice.

Authors:  Laura P Stabile; Mary E Rothstein; Phouthone Keohavong; Diana Lenzner; Stephanie R Land; Autumn L Gaither-Davis; K Jin Kim; Naftali Kaminski; Jill M Siegfried
Journal:  Cancers (Basel)       Date:  2010-12-01       Impact factor: 6.639

10.  HGF-independent potentiation of EGFR action by c-Met.

Authors:  A M Dulak; C T Gubish; L P Stabile; C Henry; J M Siegfried
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.